1. CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?. (October 2018) Authors: Daniel Francois Venter, Willem; Chersich, Matthew F; Majam, Mohammed; Akpomiemie, Godspower; Arulappan, Natasha; Moorhouse, Michelle; Mashabane, Nonkululeko; Glencross, Deborah K Journal: International journal of STD & AIDS Issue: Volume 29:Number 11(2018) Page Start: 1048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Issue 10 (October 2020) Authors: Venter, Willem D F; Sokhela, Simiso; Simmons, Bryony; Moorhouse, Michelle; Fairlie, Lee; Mashabane, Nkuli; Serenata, Celicia; Akpomiemie, Godspower; Masenya, Masebole; Qavi, Ambar; Chandiwana, Nomathemba; McCann, Kaitlyn; Norris, Shane; Chersich, Matthew; Maartens, Gary; Lalla-Edward, Samanta; Vo... Journal: Lancet Issue: Volume 7:Issue 10(2020) Page Start: e666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. (1st February 2019) Authors: Venter, Willem Daniel Francois; Kambugu, Andrew; Chersich, Matthew F.; Becker, Stephen; Hill, Andrew; Arulappan, Natasha; Moorhouse, Michelle; Majam, Mohammed; Akpomiemie, Godspower; Sokhela, Simiso; Poongulali, Selvamuthu; Feldman, Charles; Duncombe, Chris; Ripin, David H. Brown; Vos, Alinda; Ku... Journal: Journal of acquired immune deficiency syndromes Issue: Volume 80:Number 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Issue 7 (July 2019) Authors: Venter, Willem D F; Moorhouse, Michelle; Sokhela, Simiso; Serenata, Celicia; Akpomiemie, Godspower; Qavi, Ambar; Mashabane, Nonkululeko; Arulappan, Natasha; Sim, Joel W; Sinxadi, Phumla Z; Wiesner, Lubbe; Maharaj, Ellisha; Wallis, Carole; Boyles, Tom; Ripin, David; Stacey, Sarah; Chitauri, Gila; ... Journal: Lancet Issue: Volume 6:Issue 7(2019) Page Start: e428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗